Fig. 2

circGUCY1A2 exerts suppressive effects in NSCLC cells. A circGUCY1A2 expression in NSCLC cell lines and normal human bronchial epithelial cell lines. B The expressions of mRNA-GUCY1A2 and circGUCY1A2 were determined with qPCR in NSCLC cells transfected with negative control or pLCDH-circGUCY1A2. C Colony formation assay of A549, H1703 and PC-9 cells transfected with negative control or pLCDH-circGUCY1A2. D Assessment of proliferation of A549, H1703 and PC-9 cells transfected with negative cotnrol or pLCDH-circGUCY1A2 by CCK-8 assay. E NSCLC cell lines A549, H1703,and PC-9 were cultured in the presence of Cisplatin. The cells were subject to Annexin-V staining to detect apoptosis. Treatment with Cisplatin increased apoptosis. RNAs were isolated and subject to real-time PCR to measure circGUCY1A2 levels. F Apoptosis rate was analyzed by flow cytometry. NSCLC cells were transfected with negative control or pLCDH-circGUCY1A2. circGUCY1A2 enhanced cell apoptosis in NSCLC cells. G The expressions of mRNA-GUCY1A2 and circGUCY1A2 were determined with qPCR in H1299 cells transfected with negative control or si-circGUCY1A2. H Assessment of proliferation of H1299 cells transfected with negative cotnrol or si-circGUCY1A2 by CCK-8 assay. I Apoptosis rate was analyzed by flow cytometry. H1299 cells were transfected with negative control or si-circGUCY1A2. NC: negative control, scrambled sequence. Data were represented as the mean ± SEM of three independent experiments. Ns: no significance, *P < 0.05, **P < 0.01, ***P < 0.001. Error bars indicate the S.E.M